Speaker illustration

Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

Member of:

European Society of Cardiology
Heart Failure Association

Dr. Greene is a heart failure cardiologist and Associate Professor in the Division of Cardiology and Duke Clinical Research Institute, at the Duke University School of Medicine. Dr. Greene’s research focuses on improving quality of care and outcomes for patients with heart failure. He has been a co-investigator and co-author of multiple national and international heart failure trials studying medical therapies for heart failure, including the ASTRONAUT, SOCRATES-Reduced, COMPOSE, and TRANSFORM-HF trials. He has also led multiple analyses from national registries characterizing the quality of heart failure care in U.S. and global clinical practice, including studies leveraging the CHAMP-HF registry, American Heart Association’s Get With The Guidelines Heart Failure registry, the VICTORIA registry, and the CARE-HK in HF registry. Dr. Greene’s collaborative work has led to more than 350 publications in peer-reviewed journals.

Use and timing of guideline-directed medical therapy before and after hospitalization for heart failure: from the EMPACE study

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Vericiguat, SGLT2 inhibitors and implementation

Thumbnail

Optimising treatment for high-risk patients: lessons from VICTORIA

Event: Heart Failure 2025

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Pioneering advances in HFrEF management: unlocking the potential of sGC stimulation

Thumbnail

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Thumbnail

Cardiorenal pathways and characteristics of patients with coexisting heart failure and chronic kidney disease (The CaRe Study)

Event: Heart Failure 2025

Topic: Comorbidities

Session: Cardiometabolic and multisystem interactions in heart failure

Thumbnail

Ask the expert: how to optimise care for your patients with heart failure using SGLT2 inhibitors

Event: Heart Failure 2025

Topic: Chronic Heart Failure

Session: Ask the expert: how to optimise care for your patients with heart failure using SGLT2 inhibitors

Thumbnail

Shaping the future: the power of action today

Event: Heart Failure 2025

Topic: Chronic Heart Failure

Session: The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital

Thumbnail

Clinical and financial implications of inpatient and outpatient management strategies for worsening heart failure

Event: ESC Congress 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Contemporary epidemiology of worsening heart failure

Thumbnail

The risks of omission in heart failure management

Event: ESC Congress 2024

Topic: Chronic Heart Failure

Session: The risk of omission: speeding up the implementation of guideline-directed heart failure therapy

Thumbnail

Expert panel discussion and Q&A

Event: ESC Congress 2024

Topic: Pathophysiology and Mechanisms

Session: A three-step approach for the treatment of patients with worsening heart failure

Thumbnail

Step 3 - time is prognosis: rapid treatment optimisation

Event: ESC Congress 2024

Topic: Pathophysiology and Mechanisms

Session: A three-step approach for the treatment of patients with worsening heart failure

Thumbnail